Digital Marketing Efforts Prepare New Opioid Antagonist Medication to Be Ready to Take Action
Client: Hikma Pharmaceuticals
In April 2021, Hikma Pharmaceuticals received approval of Kloxxado™ (naloxone HCL) Nasal Spray 8 mg, its new opioid overdose reversal medication. At the time Narcan® was the only naloxone nasal spray on the market so swiftly building brand awareness was key to gaining market share on the opioid antagonist nasal spray leader. Embarking on a new product launch initiative is no easy task and even more complicated for a pharmaceutical drug. As its long-time digital marketing partner, Hikma knew it could count on Responsory for an agile strategy, calculated creative and quick turnaround for the naloxone nasal spray.
Responsory’s digital marketing efforts focused on building awareness of the life-saving potential of Kloxxado™ for people who are at risk of or might witness an accidental opioid overdose. With the increasing prevalence of potent, illegally-manufactured synthetic opioids, more naloxone could be required to keep someone alive or until medical help arrives or can be transferred to a medical facility. Kloxxado™ contains twice as much naloxone per spray than Narcan® (naloxone HCl) nasal spray 4 mg.1,2 This is important because 34% of opioid overdose reversals involve 2 or more doses of naloxone.3